The R&D head is looking for "clever science," which Friberg said is readily apparent in BioMarin’s recent research pact with CAMP4 Therapeutics. The partners are using CAMP4’s regulatory RNA platform ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $94.25, a high estimate of $126.00, and a low estimate of $70.00. This current ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. The company reported sales of $747 ...

BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.

Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is ...

UBS analyst Eliana Merle raised the firm’s price target on BioMarin (BMRN) to $113 from $109 and keeps a Buy rating on the shares. BioMarin ...

Citi raised the firm’s price target on BioMarin (BMRN) to $82 from $81 and keeps a Neutral rating on the shares. The company reported a Q4 ...

Biomarin Pharmaceutical has demonstrated remarkable financial performance in the fourth quarter, with net profits reaching $125 million, translating to earnings per share of $0.64—a substantial ...

Strong Q4 2024 results for BioMarin Pharmaceutical (BMRN): revenue up 18%, VOXZOGO's global growth leads the way. Discover 2025 strategies & growth targets.